Filing Flows › Dianthus Therapeutics (DNTH) › Q3 2025
Dianthus Therapeutics (DNTH) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Dianthus Therapeutics (DNTH) reported revenue of $396K for the third quarter 2025 (Q3 2025), -82% from a year earlier and +105% from the quarter before.
Dianthus Therapeutics, Q3 2025: revenue $396K (-82% year over year), net loss $36.8M, operating cash flow −$30.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $396K | +105% | -82% |
| Operating profit | −$40.3M | — | — |
| Net earnings | −$36.8M | — | — |
| Operating cash flow | −$30.6M | — | — |
What changed
Revenue was $396K in Q3 2025, down 82% year over year and up 105% from the previous quarter.
Operating costs exceeded revenue by $40.3M, an operating margin of -10173.7%. Total costs grew 27% against a revenue fall of 82%. The fastest-growing cost line was Research & development (+27%). The quarter ended with a net loss of $36.8M, wider than the previous quarter's $31.6M loss.
Operating cash flow was −$30.6M. Non-cash charges added back $27K of depreciation and $5.8M of share-based compensation. Capital expenditures of $5K exceeded it, leaving free cash flow of −$30.6M.
Questions
What was Dianthus Therapeutics' revenue in the third quarter 2025?
Dianthus Therapeutics (DNTH) reported revenue of $396K for the third quarter 2025 (Q3 2025), -82% from a year earlier and +105% from the quarter before.